亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

医学 耐受性 耐火材料(行星科学) 不利影响 细胞因子释放综合征 内科学 胃肠病学 肿瘤科 癌症 免疫疗法 嵌合抗原受体 物理 天体生物学
作者
Jesús G. Berdeja,Amrita Krishnan,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodríguez‐Otero,Elham Askari,María‐Victoria Mateos,Monique C. Minnema,Luciano J. Costa,Raluca Verona,Suzette Girgis,Thomas Prior,Brandi Hilder,Jeffery S. Russell,Jenna D. Goldberg,Ajai Chari
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 8008-8008 被引量:20
标识
DOI:10.1200/jco.2021.39.15_suppl.8008
摘要

8008 Background: New immunotherapy targets in MM are needed as patients (pts) continue to relapse. The orphan receptor GPRC5D is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T cell killing to MM cells by binding to the novel target, GPRC5D, and CD3. We present updated results of talquetamab at the recommended phase 2 dose (RP2D) from a phase 1 trial in relapsed/refractory MM. Methods: Eligible pts with MM who had relapsed or refractory disease or were intolerant to standard therapies received talquetamab intravenously (IV; range 0.5–180 µg/kg) or subcutaneously (SC; range 5.0–800 µg/kg) weekly or biweekly. Primary objectives were identification of the RP2D (part 1) and talquetamab safety and tolerability at the RP2D (part 2). Adverse events (AEs) were graded by CTCAE v4.03 (cytokine release syndrome [CRS] per Lee 2014). Response was assessed per IMWG criteria. Results: As of Feb 8, 2021, 174 pts received talquetamab, 102 by IV and 72 by SC; in parts 1 and 2, 28 pts were treated at the RP2D, identified as weekly SC 405 µg/kg, with 10.0 and 60.0 µg/kg step-up doses. Pts treated at the RP2D had a median age of 61.5 y (range 46–80) and a median of 5.5 prior lines of therapy (range 2–14; 100%/79% triple-class/penta-drug exposed; 71%/18% triple-class/penta-drug refractory; 86% refractory to last line of therapy; 21% with prior B-cell maturation antigen–directed therapy). No dose-limiting toxicities occurred at the RP2D in part 1. Most common AEs at the RP2D were CRS (79%; grade 3 4%; median time to onset: day after SC injection), neutropenia (64%; grade 3/4 54%), anemia (57%; grade 3/4 29%) and dysgeusia (57%; all grade 1/2); infections were reported in 32% of pts (grade 3/4 4%) and neurotoxicity in 7% (grade 3/4 0). In all, 75% of pts dosed at the RP2D had skin-related AEs (grade 3/4 0), including 18% with nail disorders. The overall response rate at the RP2D in response-evaluable pts (n = 24) was 63%, with 50% reaching very good partial response or better; 9/17 (53%) evaluable triple-class refractory pts and 3/3 (100%) penta-drug refractory pts had a response. Median time to first confirmed response at the RP2D was 1.0 mo (range 0.2–3.8); responses were durable and deepened over time (median follow-up 6.2 mo [range 2.7–9.7+] for responders at the RP2D). At the RP2D, exposure was maintained over the maximum EC 90 target level from an ex vivo cytotoxicity assay, and consistent T cell activation was seen. Conclusions: At the RP2D of weekly 405 µg/kg SC, talquetamab showed a high clinical response rate and was well-tolerated in pts with relapsed/refractory MM; based on pharmacokinetic data, other SC dosing strategies are being explored. The promising efficacy, safety profile and convenience of SC dosing support monotherapy development and combination approaches with this novel agent. Clinical trial information: NCT03399799.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123完成签到,获得积分10
1秒前
锅锅锅完成签到 ,获得积分10
2秒前
AiQi完成签到 ,获得积分10
3秒前
5秒前
万能图书馆的应助被吐司采纳,获得10
10秒前
海洋球发布了新的文献求助10
11秒前
dolabmu完成签到 ,获得积分10
13秒前
魔幻雅柔完成签到,获得积分10
14秒前
月亮打烊完成签到 ,获得积分10
17秒前
文静楷瑞完成签到,获得积分10
20秒前
fx完成签到 ,获得积分10
22秒前
22秒前
fantasy的应助被十三采纳,获得10
23秒前
深情安青的应助被outlast采纳,获得10
28秒前
十三完成签到,获得积分10
29秒前
30秒前
34秒前
拼搏问薇完成签到 ,获得积分10
35秒前
36秒前
Abcqqq完成签到 ,获得积分10
36秒前
海洋球完成签到,获得积分10
38秒前
ll完成签到,获得积分20
38秒前
小蘑菇的应助被xx2026采纳,获得10
39秒前
40秒前
kxz完成签到 ,获得积分10
40秒前
41秒前
gale发布了新的文献求助10
44秒前
红墨发布了新的文献求助30
45秒前
47秒前
怕黑的驳完成签到,获得积分10
48秒前
50秒前
51秒前
52秒前
53秒前
吐司发布了新的文献求助10
54秒前
冷静新烟完成签到,获得积分10
54秒前
gale完成签到,获得积分10
57秒前
1分钟前
1分钟前
TIDUS完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541